The E4 variant of the APO gene, the R47H variant of the TREM2 gene, and female sex are three of the strongest risk factors for the development of Alzheimer’s disease (AD). By combining all three of them in a mouse model of tauopathy, researchers at Weill Cornell Medical School have identified microglial inflammation and senescence as processes that occurred more strongly in female mice as tauopathy developed. Read More
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal. Read More
B-cell lymphoma 6 (BCL6) is an essential transcriptional factor for the humoral immune response. However, genomic deregulation of BCL6 contributes to the development of different types of lymphoma such as diffuse large B-cell lymphoma (DLBCL). Read More
Ichnos Glenmark Innovation (IGI) has announced a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to evaluate IGI’s selective, orally active Casitas B-lineage lymphoma b (Cbl-b) inhibitor GRC-65327. Read More
Tohoku University has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections and inflammatory disorders. Read More
Researchers from Teva Pharmaceutical Industries Ltd. have presented data from preclinical studies evaluating the novel humanized human-proteinase‑activated receptor 2 (PAR2)-specific monoclonal antibody, TEV-56192, as potential treatment of skin inflammatory conditions. Read More
UP Oncolytics Inc. has been awarded an NIH fast track grant to support the development of a treatment for glioblastoma using oncolytic Zika virus. Read More
Cartherics Pty Ltd. has raised over its target of AU$15 million (US$10.3 million) in an oversubscribed private financing round. Funding will support a clinical trial for CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases. Read More
Uereka Biosciences Inc. has synthesized mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer. Read More
Synnovation Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
Prime Medicine Inc. has announced its plans to strategically focus its efforts on a set of high value programs as it advances its pipeline of next-generation gene editing therapies. Read More
Petragen Inc. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, gingivitis, musculoskeletal and connective disorders, hematological diseases, bone, cardiovascular, immunological and neurological disorders, among others. Read More
Spima Therapeutics SAS has announced its launch with a focus on developing innovative peptide-based immunotherapies for difficult-to-reach targets, especially protein-protein interactions. Read More
